Ruiz Ana Campo, Carrascosa Miguel F, Concha Sergio Tapia, Gil Aníbal Hernández, Rivero Juan García
Department of Internal Medicine, Hospital of Laredo, Laredo, Spain.
Department of Radiology, Hospital of Laredo, Laredo, Spain.
Eur J Case Rep Intern Med. 2019 Jul 3;6(7):001131. doi: 10.12890/2019_001131. eCollection 2019.
Denosumab is an antiresorptive agent widely used for treating osteoporosis. Atypical femur fractures, osteonecrosis of the jaw and hypocalcaemia are well-known possible adverse effects of this drug. We present, to our knowledge, the first case report in the English literature of clinically significant interstitial lung disease likely related to denosumab.
Denosumab is a fully human monoclonal antibody which may rarely cause interstitial lung disease (ILD).The findings from this isolated case report of ILD in a patient taking denosumab do not prove causality.Nevertheless, we suggest that patient exposure to denosumab should be considered in a patient with ILD.
地诺单抗是一种广泛用于治疗骨质疏松症的抗吸收药物。非典型股骨骨折、颌骨坏死和低钙血症是该药物众所周知的可能不良反应。据我们所知，我们在此呈现英文文献中首例可能与地诺单抗相关的具有临床意义的间质性肺疾病病例报告。
地诺单抗是一种全人单克隆抗体，可能很少引起间质性肺疾病（ILD）。该例服用地诺单抗患者发生ILD的孤立病例报告结果并未证实因果关系。然而，我们建议对于患有ILD的患者应考虑其接触过地诺单抗的情况。
